Gilead swoops in with $567M deal to buy CAR-T 2.0 player Cell Design Labs
Gilead has swooped in on the first of several planned new buyouts to build out its CAR-T operations acquired in the $12 billion Kite buyout. And it’s starting with a company that Kite’s Arie Belldegrun believed held the key to the next-gen cell therapies that will eventually overtake the pioneers.
The company is Cell Design Labs, founded on the technology orchestrated by UC San Francisco star researcher Wendell Lim. Gilead has agreed to buy the company, launched with only $34 million in investment cash from Kleiner Perkins, Kite and others, for up to $567 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.